Interpace Biosciences, Inc. (IDXG)

Interpace Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	0.92	0.8	-5.87	-14.75	-26.2	-26.64
Depreciation & Amortization	0.8	1.03	2.56	5.37	5.5	4.19
Share-Based Compensation	0.52	0.63	1.3	1.37	2.24	1.54
Other Operating Activities	0.36	1.33	-5.69	-0.72	3.88	1.96
Operating Cash Flow	2.6	3.79	-7.69	-8.72	-14.58	-18.96
Capital Expenditures	-0.43	-0.47	-0.32	-0.35	-1.58	-0.13
Acquisitions	0.27	0.38	6.53	0.04	0	-13.83
Other Investing Activities	0.12	-	-	-	-	0.01
Investing Cash Flow	-0.05	-0.09	6.21	-0.32	-1.58	-13.95
Common Stock Issued	0	0	0.11	0.34	0.43	6.48
Share Repurchases	-0.03	-0.03	-0.11	0	-0.05	-0.04
Other Financing Activities	-5.36	-5.06	2.78	8.64	16.12	22.64
Financing Cash Flow	-5.33	-5.03	3	8.98	16.61	29.16
Net Cash Flow	-3.28	-1.83	1.51	-0.06	0.45	-3.75
Free Cash Flow	2.17	3.32	-8.01	-9.07	-16.15	-19.09
Free Cash Flow Margin	5.32%	8.25%	-25.17%	-21.96%	-49.86%	-79.27%
Free Cash Flow Per Share	0.49	0.76	-1.89	-2.19	-4.01	-5.10

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.